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Lipoprotein(a) levels in relation to albumin concentration in by a disulfide bond to a highly polymorphic glycoprotein,
childhood nephrotic syndrome. apoprotein(a) [apo(a)] [1, 2]. In the last few years, several
Background. Lipoprotein(a) [Lp(a)] is a lipoprotein con- studies have shown that Lp(a) is an independent risksisting of a low-density lipoprotein (LDL) particle linked to a
factor for atherosclerosis [3] and that plasma levels arepolymorphic glycoprotein, apoprotein(a) [apo(a)]. Prior stud-
under strict genetic control, determining interindividualies have reported high Lp(a) levels in the nephrotic syndrome,
but it is still controversial whether this is due to the degree of differences in liver synthesis [4–6]. High Lp(a) levels
hypoalbuminemia or proteinuria. have been found in patients with end-stage renal dis-
Methods. To investigate a model of nephrotic syndrome in eases, whereas after kidney transplantation, Lp(a) levelsthe absence of renal failure, we studied a group of 84 children
seem to decrease [7–9]. To explain the increase of Lp(a)in different clinical stages of the disease for a period of five
plasma levels in end-stage renal diseases, it has beenyears. We evaluated the direct relationships between lipopro-
teins, including Lp(a), and/or plasma albumin and proteinuria. suggested that the kidney might play a role in Lp(a)
Results. Lp(a) levels were significantly higher in the subjects metabolism as a catabolic site or by producing some
with the active disease compared with patients in remission, factors affecting the Lp(a) liver synthesis [10, 11].and were also significantly different when subjects were ranked
Abnormalities of apoB-containing lipoproteins areby albumin quartiles. Multiple regression analysis revealed that
common features of nephrotic syndrome [12–14]. Meta-Lp(a) levels were inversely correlated with apo(a) isoform size
and plasma albumin levels but not with the proteinuria/creati- bolic studies have shown that LDL-apoB overproduction
nine clearance ratio. Among subjects in complete remission, and/or decreased clearance are the main causes of hyper-
Lp(a) levels were different in patients with albumin levels
lipidemia in nephrotic syndrome [15–18]. However,below or above the fifth percentile. After the improvement of
whether or not hypoalbuminemia, decreased oncoticthe clinical stage of the disease, the D% variation of albumin
levels was related to the D% of apoB and LDL cholesterol pressure, and/or proteinuria are the major determinants
(LDL-C), but not with the D% variation of Lp(a), whereas the of the increased synthesis of apoB-containing particles
D% variation of LDL-C was, in turn, related to the D% of is still being debated [14–16, 19–23]. In adult patients
Lp(a) levels.
with nephrotic syndrome, Lp(a) levels are commonlyConclusions. These results suggest that in the childhood ne-
high, decreasing after remission to the control levels,phrotic syndrome, the increased Lp(a) levels are mainly related
to hypoalbuminemia, probably through a mechanism involving regardless of the type of therapy and the apo(a) pheno-
apoB overproduction, which leads to an increased number of type [18–25]. The attempt to link the Lp(a) level to pa-
LDL particles to be converted into Lp(a). rameters monitoring the stage of the disease has led to
contrasting results. Although some investigators were
able to show an association of Lp(a) with low plasma
Lipoprotein(a) [Lp(a)] is a plasma lipoprotein con- levels of albumin or degree of proteinuria, others did
sisting of a low-density lipoprotein (LDL) particle linked not confirm this significant relationship [18, 19, 24, 25].
Childhood nephrotic syndrome is an ideal model to study
the relationships between plasma lipoproteins, includingKey words: lipoprotein, childhood nephrotic syndrome, plasma albu-
min, proteinuria, hypoalbuminuria, glycoprotein. Lp(a), plasma albumin, and proteinuria, in the absence
of kidney failure. In adult nephrotic syndrome, differentReceived for publication August 27, 1998
factors may interfere in the relationship between hyper-and in revised form December 31, 1998
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the different degrees of renal failure, extension of renal 1999 by the International Society of Nephrology
2433
Noto et al: Lp(a) in nephrotic syndrome of children2434
arteriosclerosis, heterogeneity of glomerular pathology, MD, USA) for 20 hours at 50 V. At the end of the
and the presence of other diseases affecting liver func- run, the proteins were electrotransferred overnight to a
tion. In our group of children with nephrotic syndrome, polyvinylidene fluoride (PVDF) membrane (Immobilon
who were homogeneous for age range and renal pathol- P; Millipore Corporation, Bedford, MA, USA). Apo(a)
ogy and who had normal renal function, we show that was detected by a polyclonal antibody anti-apo(a). Math-
the plasma albumin level is the primary trigger of in- ematical software developed in our laboratory corrected
creased liver Lp(a) synthesis. the calibration curve for the interlane variations using
an internal standard of 39 and 13 kringles. This method
allowed us to detect at least 35 different apo(a) isoforms,METHODS
which were then coded by the number of kringle IVPatients
repeats. When heterozygous subjects were found, the
Eighty-four children, 50 males and 34 females, aged
isoform with a lower number of kringle IV repeats was8.4 6 4.9, were recruited in the outpatient clinic of the
considered to be the “smaller” isoform. The isoform withNephrology and Dialysis Division, Children Hospital
higher number of kringle IV repeats was considered to“G. Di Cristina,” Palermo, Italy. All patients had ne-
be a “larger” isoform.phrotic syndrome and were responsive to steroid therapy
according to the International Study of Kidney Disease
Statisticsin Children (ISKDC) protocols [26]. Inclusion criteria
were the absence of any systemic illness or signs of liver All variables were tested for normality performing the
diseases, diabetes, thyroid dysfunction, or familial hyper- Shapiro-Wilks normality test. Because the Lp(a) concen-
lipidemia. All patients had normal kidney function, as tration and P/CCr ratio values were not normally distrib-
defined by a creatinine clearance of more than 80 ml/ uted, a log transform was necessary to obtain a normal
min/1.73 m2. The clinical stage of nephrotic syndrome distribution in order to perform parametric tests. All of
was classified according the ratio of proteinuria/creati- the observations from the subjects were included in the
nine clearance (P/CCr) into three classes: active disease calculation; therefore, in every phase of disease, multiple
P/CCr of more than 2.0, partial remission P/CCr of more observations from individuals were evaluated together.
than 0.2 and P/CCr of less than 2.0, and complete remis- The difference between groups were investigated using
sion P/CCr of less than 0.2. The patients were investigated either the t-test or analysis of variance when more thanover a period of five years, and clinical and laboratory
two groups needed to be evaluated or when subjectsexaminations were periodically performed.
were grouped according to more than one factor (two-
way analysis of variance). The apo(a) smaller apo(a)Laboratory procedures
isoform size was denoted as the covariant variable inPlasma total protein and albumin, urinary protein, and
order to adjust the differences of Lp(a) concentrationcreatinine excretion were measured according to stan-
for the distribution of apo(a) isoforms between groups.dard procedures. Total cholesterol (TC), triglyceride
When normality tests failed because of the low number(TG), and HDL cholesterol (HDL-C) after phospho-
tungstic acid precipitation were measured using enzy- of observations within the groups, nonparametric rank
matic-colorimetric procedures [27–29]. Taking into ac- tests were performed. The degree of association between
count that Lp(a) contains 30% of cholesterol by weight, variables was assessed with Pearson’s correlation coeffi-
we calculated LDL cholesterol (LDL-C) by a modifica- cients. Nonlinear regression was performed using an ex-
tion of the Friedewald formula: LDL-C (mg/dl) 5 CHO ponential model. Independent associations between
(mg/dl) 2 TG (mg/dl)/5 2 HDL-C (mg/dl) 2 Lp (a) variables were assessed using the multiple regression
(mg/dl) 3 0.3 [30]. After the calculations, LDL-C levels analysis (MRA). Variations in the biochemical parame-
were converted in mmol/liter. ApoAI and apoB were ters in subjects switching from active disease to remission
measured by immunonephelometric methods [31]. Lp(a) during the time course of the study were evaluated as
was measured using a commercial enzyme-linked immu-
the difference of the two observations expressed in thenosorbent assay method (Macra immunoassay kit; Stra-
percentage of the value in remission (D%), and the asso-tegic Diagnostic, Newark DE, USA). Apo(a) isoform
ciation between D% variations was assessed with Pear-phenotyping was performed as previously described [32].
son’s correlation coefficients. All statistical calculationsBriefly, an aliquot of plasma normalized for Lp(a)
were performed using the Crunch 4.0 statistical packageplasma levels and containing 40 mg of apo(a) has been
from Crunch Software Corporation (Oakland, CA,loaded onto 1.5% agarose gel, 30 cm long and 5 mm thick,
USA). Nonlinear regression analysis was performed us-and was run in a horizontal electrophoretic chamber
ing Sigma Stat software from Jandel Corporation (San(GIBCO Horizon 20/25 Electrophoresis Apparatus;
GIBCO BRL Life Technologies, Inc., Gaithersburg, Rafael, CA, USA).
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Table 1. Clinical and biochemical parameters of 84 children with nephrotic syndrome according to the clinical stage of the disease
Complete Partial Active P
remission remission disease (ANOVA)
Observations 111 51 72 —
Age years 8.164.6 8.2 64.3 8.0 64.2 NS
BMI kg/m2 19.163.5 18.8 63.0 18.8 63.1 NS
P/CCr ratioa 0.05 (0.06–0.14) 0.6 (0.2–1.84)c 7.2 (2.0–246)cd ,0.0001
Albumin g/liter 4165.0 36 66.2c 2768.4cd ,0.0001
TC mmol /liter 4.7761.64 5.88 61.85c 7.2462.83cd ,0.0001
TG mmol /liter 0.9960.50 1.26 60.57c 1.6960.82cd ,0.0001
HDL-C mmol /liter 1.2960.41 1.42 60.51 1.37 60.51 NS
LDL-C mmol /liter 2.8361.34 3.63 61.52c 4.7762.81cd ,0.0001
ApoAI g/liter 1.560.34 1.6360.35 1.78 60.42c ,0.0001
ApoB g/liter 0.9360.43 1.16 60.43c 1.5060.68cd ,0.0001
Lp(a)ab mg/dl 11.0 (0.4–206) 16.4 (1–153) 18.4 (0.5–222)c 0.038
Definitions are: complete remission, P/CCr ratio , 0.2; partial remission, P/CCr ratio . 0.2 and , 2.0; active disease: P/CCr ratio . 2.0 (see Methods section for
details). Student’s t-test for independent data was used for this analysis. Abbreviations are in the Appendix.
a After log transformation; range in brackets
b Adjusted for apo(a) isoform distribution (see Statistics Section)
c P , 0.05 vs. Complete remission
d P , 0.05 vs. Partial remission
Table 2. Clinical and biochemical parameters of 84 children with nephrotic syndrome according
to quartiles of plasma albumin levels of disease
Plasma albumin g/liter
1st quartile 2nd quartile 3rd quartile 4th quartile P
,31.2 31.2–39.0 39.0–43.2 .43.2 (ANOVA)
Age years 7.564.1 7.364.2 8.764.0 9.065.0 NS
BMI, kg/m2 18.562.0 18.963.6 30.063.1 18.662.8 NS
P/CCr ratioa 3.9 (0.05–2.4) 0.6 (0.01–16.2)c 0.1 (0.009–6.2)c 0.08 (0.006–6.8)c ,0.0001
TC mmol /liter 7.9762.88 5.2661.53c 4.5661.12c 4.5661.43c ,0.0001
TG mmol /liter 1.8260.78 1.1060.54c 0.9560.37c 0.9260.40c ,0.0001
HDL-C mmol /liter 1.3860.53 1.4260.47 1.3160.47 1.2460.39 NS
LDL-C mmol /liter 5.3662.99 3.1461.12c 2.6060.89c 2.7061.14c ,0.0001
Apo AI g/liter 1.8260.42 1.6860.42 1.5060.39c 1.4360.36c ,0.0001
Apo B g/liter 1.6260.71 1.0360.35c 0.8860.40c 0.8960.34c ,0.0001
Lp(a)ab mg/dl 20.6 (0.5–222) 16.1 (0.4–210) 11.9 (2–139) 9.6 (0.5–122)d 0.01
Abbreviations are in the Appendix.
a After log transformation; range in brackets
b Adjusted for apo(a) isoform distribution (see Statistics section)
c P , 0.0001, d P , 0.05, vs. 1st albumin quartile (Student’s t-test for independent data)
Table 3. Pearson’s correlation coefficient (r) between renal functionRESULTS
monitoring parameters and lipoprotein parameters
Table 1 shows the differences in clinical characteristics
Plasma albumina P/CCr ratioband lipid and renal function monitoring parameters in
TC 20.720 c 10.462call patients, ranked by the stage of the disease according
TG 20.601c 10.416c
to the P/CCr ratio. Analysis of variance (ANOVA) HDL-C 20.050 20.053
LDL-C 20.618c 10.420cshowed that the therapy did not affect any of the investi-
Apo AI 20.303c 10.283cgated parameters, but subjects in therapy were signifi-
Apo B 20.624c 10.440c
cantly younger (data not shown). Subjects with an active Lp(a)b 20.179c 10.142d
disease had significantly higher TC, TG, LDL-C, apoB, Abbreviations are in the Appendix.
a Non-linear modelapoAI, and Lp(a), and lower albumin levels than subjects
b After log transformationin remission. Table 2 shows the behavior of the same c P , 0.0001; d P , 0.02
parameters when observations were ranked by plasma
albumin quartiles. In subjects with the lowest albumin
levels, TC, TG, LDL-C, apoB, apoAI, and Lp(a) concen-
trations were significantly greater than subjects with and did not find any difference in comparison with a
reference Sicilian population of the same age rangehigher quartile albumin levels. We also evaluated the
apo(a) isoform distributions in this group of patients, (M.R. Averna, unpublished observations). The inverse
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Table 4. Multiple regression analysis matrix table
Variables in the models
Dependent Apo(a)
variables Age BMI P/CCr ratio Albumin Lp(a) LDL-C ApoB ApoAI HDL-C TC TG isoform
Lp(a) — — — 20.291 ND — — — — (a) — 20.402
0.000 0.000
LDL-C — — — 20.175 20.116 ND 0.870 — — (a) — (b)
0.000 0.000 0.000
Apo B — — — — 0.130 0.720 ND — — (a) 0.216 (b)
0.000 0.000 0.000
Abbreviations are in the Appendix. Every row shows a single multiple regression analysis. The first column represents the dependent variable and the other
columns represent the variables included in the model using a stepwise method. b values and P values of significance are shown.
ND is the variable set as a dependent in the analysis.
(a) TC was excluded from the models, since LDL-C is a secondary variable obtained by a modification of the Friedewald formula (Methods section) and had no
tolerance in a multiple regression when TC is present.
(b) Apo(a) isoform size was included only in the analysis of Lp(a). In heterozygosis the smaller isoform was used for the calculations [32].
correlation of Lp(a) levels with apo(a) isoforms [4] was lated positively with the apo(a) isoform size. Finally, the
percentage of proteinuria changes expressed as themaintained in both remission and active nephrotic syn-
drome. A slope test (remission, slope 5 20.113 vs. active P/CCr ratio were never found to be correlated with the
Lp(a) changes (data not shown).disease, slope 5 20.117) showed no significant difference
between the regression lines. Table 3 shows the correla-
tion of the two main parameters monitoring the stage
DISCUSSION
of disease, albuminemia and P/CCr ratio, with the lipid
Several studies have investigated the alterations ofand lipoprotein values. To better describe the association
Lp(a) in renal diseases. Studies investigating lipoproteinof plasma albumin with the investigated parameters, a
abnormalities in renal diseases with nephrosis havenonlinear exponential model of regression was used. In
shown a consistent increase of plasma Lp(a) that paral-this univariate analysis, lipids and lipoproteins were
lels the increase of cholesterol, TG, and apoB [12–19].more correlated with plasma albumin than with the
Nevertheless, there is no current agreement aboutP/CCr ratio. A series of MRAs was performed to more
whether hyperlipidemia of the nephrotic syndrome is aclosely estimate the independent relationships among
consequence of an impaired renal function or whetherthe studied parameters and, in particular, to determine
it is due to the plasma albumin decrease, to orosomucoidsthe independent association of albuminemia and the
levels, or to other unknown plasmatic factors [20–23].P/CCr ratio with the main lipid and lipo-apoprotein pa-
The aim of this study was to determine the role of plasmarameters. These multiple regression analyses are ar-
albumin and/or proteinuria as a trigger for the Lp(a)ranged in a matrix table (Table 4). Albumin levels corre-
increase in nephrotic syndrome. The studied populationlated independently with Lp(a) and LDL-C, whereas the
was very homogeneous, and subjects were in a narrowP/CCr ratio was not significantly correlated with any pa-
range of age. All of them were suffering from a primitiverameter. In Table 5, all of the subjects ranked as being
nephrotic syndrome, according to their susceptibility toin remission (the P/CCr ratio was within the normal range)
the steroid therapy [25]. Moreover, some of the patientswere grouped into two plasma albumin groups using a
underwent a renal biopsy, which showed a minimal lesionplasma albumin level of 30 g/liter as a cut-off, which is
renal disease. None of the monitoring parameters exam-the fifth percentile of the present albumin distribution
ined could reveal a gross alteration of the renal function.in the remitted subjects. The data showed that in spite
Lp(a) was significantly increased when subjects wereof the normal P/CCr ratio, subjects with low albumin had
ranked by the P/CCr ratio but was negatively correlatedsignificantly higher TC, TG, apoB, and Lp(a) levels than
to the quartiles of albuminemia, reaching the highestthose with high albumin. A follow-up analysis was per-
concentrations in the lowest albumin quartile. The Pear-formed in the subjects (N 5 24) who switched from the
son’s correlation statistical analysis and the MRA con-active phase of disease to remission in the time course
firmed these results. According to other studies, our dataof the study. The results are summarized in Table 6. The
also show a significant increase of TC, TG, LDL-C, apoB,main finding was that a plasma albumin D% decrease
and apoAI when subjects were in active nephrotic syn-correlated with the D% increase of apoB and LDL-C
drome. Some authors could not find any correlation be-levels but not with the D% variations of Lp(a) levels,
tween albuminemia, proteinuria, and degree of hyperlip-whereas the D% LDL-C increase, in turn, did correlate
idemia [19, 24, 33]. The reason for this discrepancy maywith the Lp(a) D% increase. Noteworthy is the fact that
the D% increase of Lp(a) plasma concentrations corre- reside in the age of the subjects, who were mostly adults
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Table 5. Clinical and biochemical parameters observed in 84 children with nephrotic syndrome in complete remission (P/CCr ratio , 0.2)
showing plasma albumin levels above or under the 5th percentile
Plasma albumin g/liter
,5th percentile (,30.4) .5th percentile (.30.4) P
Observations 7 104
Age years 4.562.1 7.2 63.9 NS
BMI kg/m2 17.363.7 17.2 63.4 NS
P/CCr ratioa 0.07 (0.01–0.14) 0.05 (0.006–0.19) NS
TC mmol /liter 7.5062.96 4.56 61.44 ,0.01
TG mmol /liter 1.5560.93 0.93 60.44 ,0.05
HDL-C mmol /liter 1.5960.42 1.28 60.42 NS
LDL-C mmol /liter 4.7262.68 2.68 61.14 NS
ApoAI g/liter 1.7960.90 1.49 60.39 NS
ApoB g/liter 1.5860.87 0.88 60.38 ,0.05
Lp(a)ab mg/dl 55.2 (1.0–207) 12.7 (0.4–122) ,0.05
Apo(a) size, kringles 27.263.2 26.2 64.7 NS
The Mann-Whitney U test was used due to the low number of observations in the , 5th percentile albumin group. Abbreviations are in the Appendix.
a Means are calculated from the mean of log transformed values; range in brackets
b Adjusted for apo(a) isoform distribution (see Statistics section)
Table 6. Pearson’s coefficients of the main correlations of individual teins. Albumin was inversely correlated to the increase
D% variations of biochemical parameters in 24 subjects switching
of Lp(a), TC, and LDL-C, whereas the P/CCr ratio wasfrom remission to active nephrotic syndrome
never correlated to any of these parameters. We specu-
Pearson’s r lated that a proper analysis of the changes of Lp(a)
Albumin vs. Apo B 20.738a and other lipoproteins in nephrotic syndrome could be
Albumin vs. LDL-C 20.664c
achieved in individual patients following the switchingAlbumin vs. Lp(a) NS
Albumin vs. TG 20.681b from remission to relapse. Therefore, we isolated 24 indi-
Apo B vs. LDL-C 10.843a viduals who experienced both disease phases in the
Apo B vs. Lp(a) NS
course of the study. In order to compare the differentLDL-C vs. Lp(a) 10.447d
Apo(a) isoform vs. Lp(a) 10.564c patterns of these subjects, every parameter assayed was
D% variations are expressed as percent of the remission value of the investi- expressed as a percentage of its basal value. When the
gated parameters in every subject. Abbreviations are in the Appendix. D% variations of the different parameters were corre-a P , 0.0001; b P , 0.001; c P , 0.01; d P , 0.05
lated, we could isolate a pattern of correlation that fit
in a pathophysiological model. In fact, the entity of the
decrease of plasma albumin was linked only to a propor-
tional increase of apoB, which was linked to the in-with a different degree of renal impairment and with
creased levels of LDL-C, and the latter were finally re-different renal pathology. Querfeld et al studied a group
lated to the Lp(a) increases. In addition, we found aof young nephrotic patients with chronic renal failure
positive correlation between the Lp(a) level changes andwho underwent continuous ambulatory peritoneal dial-
the apo(a) isoform size. The correlation of the individualysis or renal transplantation [34]. Their data show an
LDL increase with Lp(a) increase does not seem to beinverse association of Lp(a) levels with the apo(a) iso-
consistent with the weak inverse correlation of the twoform size. When we analyzed our subjects in remission,
parameters in the overall MRA. To explain this apparentwe could isolate a subgroup of patients with low albumi-
discrepancy, we reasoned that high levels of apoB leadnemia and normal P/CCr ratio. These subjects showed an
to an elevated number of LDL particles, and this event,abnormal lipid pattern with significantly increased levels
of Lp(a), although they were classified as being in remis- in turn, increases the number of Lp(a) particles assem-
bled, as suggested by the correlation obtained by individ-sion. Therefore, in this subset of patients, the remission
of proteinuria, as monitored by the P/CCr ratio, was not ually analyzing the patients. Although in normal condi-
tions Lp(a)-apoB represents a negligible amount of thefollowed by Lp(a) changes that seemed to be related to
the low plasma albumin levels. Consistent with our re- LDL-apoB-pool, it is likely that in subjects with elevated
Lp(a) levels, the increased number of Lp(a) particlessults, Joven et al found that a period of hyperlipidemia
follows the fall of proteinuria into the normal range, and may sensibly affect the number of LDL particles left in
the plasma so that Lp(a) is still positively linked to apoBit appears to be related to a persistence of low albumin
and impaired TG-rich lipoprotein catabolism [35]. Multi- but weakly and inversely to LDL-C levels. These data
strongly support the hypothesis that the degree of hypo-ple regression analyses were performed to evaluate
which parameters linked better to lipids and apo-lipopro- albuminemia is the first step leading to the Lp(a) plasma
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APPENDIXcentrations inhibited the apoB liver output [36]. They
Abbreviations used in this article are: apoAI and B, apoproteinsalso showed that apoB overproduction induced by
AI and B; BMI, body mass index; CCr, creatinine clearance; HDL,oleate/BSA is linked to the suppression of intracellular high density lipoprotein; HDL-C, high density lipoprotein-cholesterol;
apoB degradation. In addition, Zaiou et al have recently LDL, low density lipoprotein; LDL-C, low density lipoprotein-choles-
terol; Lp(a), lipoprotein(a); MRA, multiple regression analysis; NS,shown that the human apoA-I gene is overexpressed in
not significant; P/CCr, proteinuria/creatinine clearance ratio; TC, totalthe experimental nephrotic syndrome of apoAI trans- cholesterol; TG, triglyceride.
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